Skip to main content
PHYSIOMICS PLC logo

PHYSIOMICS PLC — Investor Relations & Filings

Ticker · PYC ISIN · GB00BDR6W943 LEI · 213800A71DSZ6ABMTQ91 IL Professional, scientific and technical activities
Open in API
Filings indexed 332 across all filing types
Latest filing 2015-11-27 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL PYC

About PHYSIOMICS PLC

https://www.physiomics.co.uk/

Physiomics PLC is a data-driven consultancy that provides Model-Informed Drug Development (MIDD) services to pharmaceutical and biotechnology companies. The company specializes in accelerating and de-risking the development of new drugs by integrating expertise in Modelling & Simulation, Biostatistics, and Data Science. By applying quantitative pharmacology and pharmacokinetic/pharmacodynamic (PK/PD) modelling, Physiomics supports clients in making smarter, data-driven decisions throughout the drug development pipeline, from preclinical discovery to clinical trials. The company has a notable focus on oncology, leveraging advanced computational biology platforms to optimize treatment strategies and predict patient outcomes.

Recent filings

Filing Released Lang Actions
Notice of General Meeting
Share Issue/Capital Change Classification · 1% confidence The document is identified by the 'RNS Number' header and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content announces a 'Notice of General Meeting' to consider a 'Share Capital Reorganisation' (subdivision of shares). This is a formal regulatory announcement regarding a corporate action (share structure change) disseminated via the Regulatory News Service (RNS). While it relates to capital structure, the primary nature of the document is the announcement itself, disseminated through the RNS system, making 'RNS' the most appropriate general classification, although 'SHA' (Share Issue/Capital Change) is also relevant. Given the explicit RNS formatting and context, RNS is chosen as the primary filing type for regulatory dissemination.
2015-11-27 English
Final Results
Annual Report Classification · 1% confidence The document is titled 'Final Results for the year ended 30 June 2015' and contains comprehensive financial statements including an Income Statement, Statement of Financial Position, Statement of Changes in Equity, and Cash Flow Statement. Although it is presented via an RNS (Regulatory News Service) feed, it provides the full substantive financial data for the fiscal year, distinguishing it from a mere announcement of a report. Given it covers a full fiscal year and provides detailed financial performance, it is classified as an Annual Report (10-K equivalent for this jurisdiction). FY 2015
2015-11-10 English
Strategic Update
M&A Activity Classification · 1% confidence The document is identified by the RNS Number header and the 'END' marker typical of regulatory news service announcements. The content provides a 'Strategic Update' regarding M&A targets and also states that the company 'anticipates releasing its Annual Results for the year ended 30 June 2015 shortly.' Since the document is short (3177 chars) and primarily serves as an update announcing future actions and results release timing, rather than being the full Annual Results document itself, it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific mention of announcing the upcoming release of Annual Results, RPA is highly appropriate, but RNS is the general category for LSE news service releases. Since the core content is a strategic update and an announcement about a future report release, RNS is the most fitting general category for this type of LSE news wire filing.
2015-11-06 English
4th Large Pharma Customer for Virtual Tumour
Regulatory Filings Classification · 1% confidence The document is very short (2567 characters) and begins with an 'RNS Number' (8746B) and a date (12 October 2015). The content announces a new business contract ('signed a new Virtual Tumour deal with a new pharmaceutical company'). This structure—a brief announcement of a specific, non-financial event released via the RNS system—fits the definition of a general regulatory announcement that doesn't fit a more specific category like ER, DIV, or CAP. Therefore, it should be classified as a Regulatory Filing (RNS).
2015-10-12 English
Project extension with global pharma company
Regulatory Filings Classification · 1% confidence The document is a formal announcement disseminated via 'RNS Number', which stands for Regulatory News Service, a common channel for UK listed companies. The content announces a business update: the signing of a project extension with a global pharma company. This is a material, non-financial operational update. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A). Since it is a general regulatory announcement that doesn't fit into the more specific operational or financial categories, the most appropriate classification is the general regulatory filing category, RNS.
2015-10-09 English
Prof. Mark Middleton appointed to Physiomics SAB
Board/Management Information Classification · 1% confidence The document is identified by the 'RNS Number : 9498U' header, indicating it is a regulatory news service announcement from the London Stock Exchange. The content announces the appointment of Professor Mark Middleton to the company's Scientific Advisory Board (SAB). This type of announcement—a change in key personnel or advisory structure—fits best under the 'Board/Management Information' category (MANG). Although it is an RNS filing, MANG is more specific than the general RNS fallback. The document is short and contains the news directly, not just an announcement of another report.
2015-08-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.